Shares in Baxter (NYSE:BAX) fell slightly this morning after the company topped expectations on Wall Street with its fourth quarter and full-year results.
The Deerfield, Ill.-based company swung to a loss in Q4 thanks to a $322 million hit from the recently-enacted U.S. tax reform legislation. Baxter posted -$71 million in net losses for the quarter on sales of $2.77 billion for the 3 months ended Dec. 31, for sales growth of 5% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
